Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.37 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3814969 | 0.98 | RAB9A (0.38) | RAB9APOLBL3MBTL1HCRTR2PEPD | |
| SCHEMBL3813322 | 0.79 | RAB9A (0.44) | RAB9AHCRTR2PEPDDPP4 | |
| SCHEMBL27904262 | 0.77 | RAB9A (0.60) | RAB9APEPD | |
| SCHEMBL4576862 | 0.77 | RAB9A (0.64) | RAB9APOLBL3MBTL1HCRTR2DPP4 | |
| SCHEMBL27922142 | 0.76 | RAB9A (0.44) | RAB9AHCRTR2PEPDHTTPREP | |
| SCHEMBL22082567 | 0.76 | POLB (0.43) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL337037 | 0.75 | HSD17B10 (0.48) | L3MBTL1 | |
| SCHEMBL337349 | 0.75 | HSD17B10 (0.48) | L3MBTL1 | |
| SCHEMBL205359 | 0.75 | HSD17B10 (0.48) | L3MBTL1 | |
| SCHEMBL3810806 | 0.75 | DPP4 (0.48) | DPP4PREPFAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281352-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVES HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATES FOR PRODUCTION OF THE DERIVATIVES | MITSUI CHEMICALS, INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281352-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVES HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATES FOR PRODUCTION OF THE DERIVATIVES | MITSUI CHEMICALS, INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2008997-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVE HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATED FOR PRODUCTION OF THE DERIVATIVE | Mitsui Chemicals, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281352-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVES HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATES FOR PRODUCTION OF THE DERIVATIVES | ASNS, GLUL, NAAA | RAB9A 3162/4885POLB 570/4885L3MBTL1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.